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Abstract
Background: Decision aids (DA) are tools designed to help patients make specific and deliberative
choices among disease management options. DAs can improve the quality of decision-making and
reduce decisional conflict. An area not covered by a DA is the decision of a patient with chronic
obstructive pulmonary disease (COPD) to use inhaled steroids which requires balancing the
benefits and downsides of therapy.
Methods: We developed a DA for COPD patients considering inhaled steroid therapy using the
Ottawa Decision Support Framework, the best available evidence for using inhaled steroid in
COPD and the expected utility model. The development process involved patients,
pulmonologists, DA developers and decision making experts. We pilot tested the DA with 8
COPD patients who completed an evaluation questionnaire, a knowledge scale, and a validated
decisional conflict scale.
Results: The DA is a computer-based interactive tool incorporating four different decision making
models. In the first part, the DA provides information about COPD as a disease, the different
treatment options, and the benefits and downsides of using inhaled steroids. In the second part, it
coaches the patient in the decision making process through clarifying values and preferences.
Patients evaluated 10 out of 13 items of the DA positively and showed significant improvement on
both the knowledge scale (p = 0.008) and the decisional conflict scale (p = 0.008).
Conclusion:  We have developed a computer-based interactive DA for COPD patients
considering inhaled steroids serving as a model for other DAs in COPD, in particular related to
inhaled therapies. Future research should assess the DA effectiveness.
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Background
Increasingly, patients want to become actively involved in
medical decision-making [1]. Active patient involvement
can improve outcomes including quality of life and can
possibly reduce health care expenditures [2-4]. However,
therapy and screening decisions are complicated for sev-
eral reasons. First, there is often no single 'best' choice
because people vary in the values or personal importance
that they place on the benefits and harms of different
treatment or screening options. Second, the evidence
needed to trade off benefits and downsides (harm, burden
and cost) of options may be of low quality. Third, clini-
cians have little knowledge about the best ways to present
evidence and to involve patients in the decision making
process. Individual practice circumstances further compli-
cate evidence based decision making.
Because of the existing evidence that active patient
involvement can improve outcomes [2-4] and in order to
help people make wise choices among options [5,6]
investigators and clinicians have developed decision aids
(DAs). DAs are decision support tools that provide
patients with detailed and specific information on
options and outcomes, help them clarify their values, and
guide them through the decision making process [7]. DAs
are superior to usual care interventions in improving
knowledge and realistic expectations of the benefits and
harms of options; reducing passivity in decision making;
and lowering decisional conflict due to feeling unin-
formed [7]. Additionally, they assist patients with chronic
diseases in feeling better socially supported and poten-
tially improving their behavioral and clinical outcomes
[8].
Chronic Obstructive Pulmonary Disease (COPD) is a
major cause of chronic morbidity and mortality through-
out the world [9]. In the US alone, COPD affected an esti-
mated 11 million adults in 2002, and was the fourth
leading cause of death in 2004 [10]. The 2004 US expen-
ditures for health and lost productivity due to COPD were
estimated at $37.2 billions [10]. Further increases in
COPD prevalence and mortality will occur in the coming
decades [11].
Inhaled steroids, one of therapeutic options for COPD,
reduce the number of acute exacerbations in COPD
patients [12,13] and have a small beneficial effect on their
health related quality of life (HRQL), but have a number
of side effects including oropharyngeal candidiasis and
skin bruising [12]. They also pose the additional burden
of using an inhaler. Asking COPD patients to decide
about starting inhaled steroids implies a decision making
process trying to balance the benefits and harms by
including their personal values. Although we did not
identify any study about the difficulties with making such
a decision, we had noted difficulties in the course of our
clinical practice and when speaking to colleagues. In this
paper we describe the development and pilot testing of a
decision aid for COPD patients considering inhaled ster-
oids therapy that can serve as a model for other decisions
aids in COPD.
Methods
Development of the Decision Aid
The development of the COPD DA consisted of five steps:
(1) Structural development: the structure of the DA follows
the Ottawa Decision Support Framework (DSF) [14] and
is based on the Ottawa Personal Decision Guide (OPDG)
[15]. The framework is an evidence-based, practical, mid-
range theory for guiding patients making health or social
decisions. Mid-range theories are moderately abstract and
inclusive theories that address specific phenomena and
are composed of concepts and propositions that are meas-
urable [16]. The framework supports decision making
through providing information about the disease, its
treatment alternatives and the associated outcomes;
through clarifying values; and finally through augmenting
skills in decision making. The Ottawa Personal Decision
Guide (OPDG) is a generic decision aid designed for any
health-related and/or social decision. It helps people
assess their decision making needs, plan the next steps,
and track their progress in decision making. However, it
does not include standardized guidance about how to
include an interactive computer based interface, which
was one of the aims of our project. Furthermore, opposed
to the generic features of the OPDG we aimed to include
different decision making models in the aid. The latter
was another of our specific aims for this decision aid and
the intended decision making process.
(2) Information compilation: we derived the information
about the outcomes of inhaled steroids treatment in
COPD patients from the most recent systematic review of
the medical literature about the topic [12], and from sev-
eral of the original studies included in the review. Benefi-
cial outcomes include a reduction in the rate of
exacerbations (RR = 0.70; 95% CI: 0.58 to 0.84: from 0.8
to 0.56 exacerbation per year) [12] and a deceleration in
the rate of decline in health status [17]. Harms include
increases in the rates of oropharyngeal candidiasis (RR =
2.1; from 0.8% to 1.7% per year), skin bruising (RR = 2.1;
from 1.0% to 2.1% per year) and dysphonia (RR = 2.0;
from 1.7% to 3.3% per year) as well as the burden of using
the drug. We also included a statement about the uncer-
tainty of the effect of inhaled steroids on mortality, cata-
ract and bone fractures [18].
(3) Platform design: two professional web designers expe-
rienced health related websites developed the platform ofBMC Medical Informatics and Decision Making 2007, 7:12 http://www.biomedcentral.com/1472-6947/7/12
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the DA using Macromedia Dreamweaver 2002 software.
They developed it as a CD-ROM version and then made it
available on the World Wide Web.
(4) Experts' feedback: we consulted pulmonologists, med-
ical decision making experts (Drs. Amiram Gafni and
Cathy Charles, McMaster University, Hamilton, Canada)
and a DA expert (Dr. Annette O'Connor, University at
Ottawa, Canada). We used their in-depth feedback to
improve different aspects of the DA. These improvements
related to the structure of the decision aid and the integra-
tion of different decision making models.
(5) Patients' feedback: we conducted detailed interviews
with 7 COPD patients. Each patient reviewed the DA,
answered specific questions and provided general com-
ments. After each interview, we made modifications based
on the patient feedback. Modifications were mainly
related to the use of lay terms, the form of presentation of
the statistical presentation, and the amount of informa-
tion.
Pilot testing of the Decision Aid
Eight additional COPD patients used the DA as if they
were to make a real life decision about the use of inhaled
steroids. These participants completed 3 instruments: (1)
an evaluation questionnaire; (2) a knowledge scale
(before and after use); and (3) a validated decisional con-
flict scale (before and after use) [19]. The evaluation ques-
tionnaire addressed 13 features of the DA that participants
rated on 5-point Likert scales (1 for lowest value, 3 for
neutral value and 5 for highest value). The knowledge
scale consisted of 10 questions we developed specifically
about the use of inhaled steroids in COPD patients [see
Additional file 1]. We kept track of the required time and
the need for assistance in using the DA. The State Univer-
sity of New York at Buffalo and the Buffalo Veterans
Affairs Medical Center institutional review boards (IRB)
approved this study and all participants provided
informed consent.
Statistical analysis
For the 5 point Likert scale questions, we used a one sam-
ple t-test to compare the mean response to 3 (neutral
value). For the knowledge and decisional conflict scales,
we used a paired t-test to compare the pre and post inter-
vention mean scores. We used SPSS, version 11.0 (SPSS,
Inc., Chicago, Illinois) and considered p < 0.01 (two-
sided) as statistically significant.
Results
The decision Aid [20]
Structure
The DA is structured in two parts, each part consists of sev-
eral sections, and each section consists of several pages
(Figure 1) [see Additional file 2]. In the first part, the DA
provides medical information about: the use of the DA,
COPD, treatment alternatives, the benefits of inhaled ster-
oids, and their downsides. In the second part, the DA
coaches the patient in the decision making process
through: case scenarios of hypothetical COPD patients
using their values to make tradeoffs between the benefits
and harms of the inhaled steroids, clarification of the
patient's own values for each benefit and harm (see "rat-
ing values"); and assistance in the final decision making
(see "Decision making models").
Rating values
The DA asks the patient to assign the value she attaches to
each of the potential outcomes (benefits and harms) of
using inhaled steroids. The value rating instrument is a
horizontal feeling-thermometer with values ranging from
0 ("death") to 100 ("Full Health") by increments of 1
unit. The patient moves the cursor of the scale to assign
her value for a specific outcome. A box adjacent to the
scale indicates the exact value being assigned. The scales
for the different outcomes are stacked vertically to enable
the patient to compare them visually. (Figure 2)
Decision making models
The DA, by providing the medical information and clari-
fying patient values, allows the patient to choose one of
four possible decision making models[21,22] Under the
"informed decision making model" the patient opts for
integrating herself the medical information with her val-
ues to make a decision. Under the "physician as an agent
model" the patient opts for the DA to integrate the infor-
mation and the values and provide a recommendation "to
use" or "not to use" inhaled steroids. This recommenda-
tion is determined by a decision analysis combining out-
comes probabilities and the patient assigned values (the
expected utility theory). Under the "shared decision mak-
ing model" the patient reviews the medical information in
the DA and goes through the value clarification process,
first, and then and makes the decision together with his
health care provider. Finally, under the "paternalistic
model" the patient can quit the DA at any time and leave
the entire decision to her health care provider. (Figure 3)
Navigation
The user can access the first page of any section from any
page of the DA, and all pages of a particular section from
any page of that section. Additional features include
hyperlinks to references and definitions of technical
words that pop-up in small-size windows. The navigation
thus permits access to medical information when needed
at any step of the DA.BMC Medical Informatics and Decision Making 2007, 7:12 http://www.biomedcentral.com/1472-6947/7/12
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Pilot testing of the Decision Aid
Table 1 lists the characteristics of the patients who partic-
ipated in the pilot testing of the DA. Table 2 lists the
results of the pilot testing. Participants provided positive
feedback regarding the design, pictures, understandabil-
ity, user friendliness, perceived required time, explana-
tions, and amount of information in the DA. They felt
comfortable and satisfied using it. However they had neu-
tral opinion about the clarity of statistical explanations,
the explanation of the concept of values, the helpfulness
of the DA and the perceived improvement in knowledge.
Both the knowledge and the decisional conflict scales
improved significantly after review of the DA. The mean
needed time to finish reviewing the DA was 32 min and
75% of patients needed assistance in using the appropri-
ate buttons to navigate the DA.
Discussion
We have developed a DA for COPD patients considering
inhaled steroid therapy. The DA is a computer-based
interactive tool structured following the Ottawa Decision
Support Framework and integrating four decision-making
models (the paternalistic model, the informed decision
making model, the physician as an agent model and the
shared decision making model). In practice, patients
could briefly review the DA with the health care provider
at the time of the medical encounter and then complete a
detailed review on their own. The most efficient way of
completing the decision aid is thus one that does not
require presence of a health care provider. COPD patients
evaluated positively most of the features of the DA, and
showed significant improvement on both the knowledge
and the decisional conflict scales.
The DA has several strengths. First, it meets 14 of the 23
quality criteria for "content" and 15 of the 19 quality cri-
teria for "development process" recently proposed by the
International Patient Decision Aid Standards (IPDAS)
Collaboration [23]. Second, we used a rigorous evidence-
based approach to gather and summarize the evidence
provided in the decision aid. Third, we have integrated
into the decision aid several decision making models to
respond to different decision making preferences. We
know of no other decision support tool that provides this
flexibility, which responds to the variability in decision-
making style preferences among patients [24]. Fourth, we
Screenshot showing the general appearance and structure of the DA Figure 1
Screenshot showing the general appearance and structure of the DA.BMC Medical Informatics and Decision Making 2007, 7:12 http://www.biomedcentral.com/1472-6947/7/12
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assessed patient values using a quantitative method. Fifth,
the computer-based format offers the advantages of ease
of access, convenience, and ease of update.
The decision aid has some limitations. First, we have not
evaluated yet the effectiveness of the DA in terms of the
impact on the decision processes or decision quality.
While the pilot testing in 8 patients provided us with
important information, it is insufficient for claiming its
widespread use. Second, the computer-based format of
the DA might not be ideal for older patients. However, the
proportion of COPD patients who are computer literate should
be on the rise. Third, the DA does not individualize the risk
of developing specific outcomes as in other DAs [25]. We
would integrate such function when the necessary statisti-
cal prediction models become available.
Other DA developers have also described the challenge of
how to communicate risk to patients [24,26]. While the
literature suggests that different presentation formats lead
to different decisions [27], we do not know which format
promotes decisions most consistent with patient values
and preferences. An international series of randomized
trials (Health Information Project: Presentation Online or
HIPPO) are currently underway to try to answer that ques-
tion [28].
Wilson et al. developed a DA to assist patients with COPD
in advance planning for life-threatening exacerbations of
their disease [29]. For patients participating in an evalua-
tion study of the decision aid, the burden of treatment
(mechanical ventilation in that case) was also an impor-
tant consideration in making the decision. In addition,
about a quarter of patients in that study did not com-
pletely comprehend the DA suggesting that this relatively
older population might find it challenging to use decision
support tools.
This DA may benefit patients with a baseline uncertainty
about their choice, similarly to findings in studies of other
Screenshot showing the value rating instrument Figure 2
Screenshot showing the value rating instrument.BMC Medical Informatics and Decision Making 2007, 7:12 http://www.biomedcentral.com/1472-6947/7/12
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DAs [30]. Patients who have strong prior preference may
still benefit from the medical information the DA pro-
vides. The DA will also benefit patients who want to be
involved in decision making given patients vary in their
preferences for such involvement [31].
Conclusion
We are planning to conduct a pragmatic clinical trial eval-
uating the impact of the decision aid on decision proc-
esses and decision quality [32]. In that trial we intend to
compare different formats of the DA (computer based,
paper based) in order to identify the most cost effective
option [33]. The DA presents an opportunity to study dif-
ferent ways of presenting information and of eliciting val-
ues and evaluate their effect on the decision making
process comparatively. It can also serve as a template for
the development of other DAs related to emerging COPD
treatments that involve a benefit risk tradeoff (e.g. pro-
tease inhibitors).
Disclaimer
The Decision Aid for making decisions about using
inhaled steroids in COPD (DA) is not a substitute for
medical advice, examination, diagnosis treatment or judg-
ment of a physician or health care professional. If you
have any concerns about your health, talk to a doctor.
Also, do not disregard or delay seeking medical advice
because of something you read on the DA. The informa-
tion found on the DA is to be used solely for informa-
tional purposes. Additionally, in spite of our best efforts,
the information in the DA may become out of date over
time. The DA team accepts no liability for the accuracy or
completeness or use of, nor any liability to update, the
information or materials provided in the DA.
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Table 1: Baseline characteristics of pilot testing patients
Variable Respondents (N= 8)
Mean (SD)
Age 69 (7.2)
n (%)
Gender (Female) 3 (37.5)
Educational level
Less than high school 1 (12.5)
high school 5 (62.5)
College 1 (12.5)
graduate degree 1 (12.5)
Ethnic group
Caucasian 7 (87.5)
African-American 1 (12.5)
Computer user 2 (25.0)
Internet user 1 (12.5)
Table 2: Results of the pilot testing
Variable Value P value
Design 4.1 (0.6) 0.002
Pictures 4.5 (0.5) 0.000
Understandability 4.4 (0.5) 0.000
User Friendliness 4.5 (0.5) 0.000
Perceived required time 4.6 (0.5) 0.000
Explanation 4.4 (0.5) 0.000
Amount of information 4.8 (0.5) 0.000
Statistical information clarity 3.9 (1.2) 0.111
Concept of values explanation 3.8 (1.0) 0.080
Comfortable using the Aid 4.5 (0.5) 0.000
Decision Aid helpfulness 3.8 (1.3) 0.008
Knowledge improvement 3.9 (1.0) 0.041
Satisfaction 4.3 (0.7) 0.002
Knowledge scale Pre * 4.3 (1.6) 0.008
Knowledge scale Post 6.8 (0.9)
Decisional Conflict scale Pre § 2.4 (0.7) 0.008
Decisional Conflict scale Post 1.5 (0.4)
Number of minutes to complete the DA mean (sd) 32.0 (4.5) N/A
Need for assistance to use the DA n (%) 6 (75%)
* Min = 0; Max = 10
§ 5 point Likert scale with 1 = low decisional conflict score; 5 = high decisional conflict score.BMC Medical Informatics and Decision Making 2007, 7:12 http://www.biomedcentral.com/1472-6947/7/12
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